ISAL 2019 | Clonal interference of signaling mutations in AML: impacts on outcome
Raphael Itzykson, MD, PhD, of Hôpital Saint-Louis, Paris, France, discusses the clonal interference of signaling mutations in acute myeloid leukemia (AML). His group identified a subset of CBF-AML patients that harbor several signaling gene mutations, which arose in independent clones. Prof. Itzykson discusses the impacts of this clonal interference on long-term outcomes, and further research planned in this area. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up